Form4insider filings, from the source

SEC Form 4 · accession 0001366074-26-000002

Inhibrx Biosciences, Inc. · INBX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mark Lappe
Officer — Chief Executive Officer · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 8, 2026 · 4:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002007919

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Sep 8, 2026P5,895$99.2948A711,443IBy the Lappe Family Trust
Common StockF3,F2Sep 8, 2026P6,605$100.6388A718,048IBy the Lappe Family Trust
Common StockF4,F2Sep 8, 2026P1,100$107.1239A719,148IBy the Lappe Family Trust
Common StockF5,F2Sep 8, 2026P500$108.235A719,648IBy the Lappe Family Trust
Common StockF6,F2Sep 8, 2026P1,219$111.8805A720,867IBy the Lappe Family Trust
Common StockF7,F2Sep 8, 2026P9,681$112.2819A730,548IBy the Lappe Family Trust
Common StockF8holding———165,000IBy Lappe Descendants' Trust
Common Stockholding———54,865IThe Mark Paul Lappe Roth IRA

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses